The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
Investors in United Therapeutics Corp (Symbol: UTHR) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is ...
Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
United Airlines said it has apologized to a woman who felt "humiliated" when crew members tried to get her to remove her son's ventilator on a flight this month. Melissa Sotomayor said in a now ...
Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults ...